In collaboration with the American Association for Cancer Research, a global leader in cancer research, we've presented Dr. Wang with the 2024 Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research. Through this groundbreaking work, Dr. Wang seeks to prevent cancer in patients with Fanconi...
Supported Research
-
-
This supplemental funding builds on the groundwork laid by the 2022 grant awarded to Drs. Markus Grompe and Raymond Monnat, titled Oral Mucosal Gene Therapy as a Prevention for FA-Associated Cancers. The proposed research focuses on reducing the risk of squamous cell carcinoma (SCC) in...
-
This supplemental funding builds on the work from the 2020 Fanconi Cancer Foundation grant awarded to Dr. Grompe, titled Chemoprevention of Cancer in Fanconi Anemia, and additional research supported by the Stand Up To Cancer head and neck cancer team in 2022. Chemoprevention studies are...
-
This is an extension of a project funded in 2023. Correcting FA mutations in all cells of the body may prevent issues such as bone marrow failure and cancer in people with FA. Since mutations in FA genes start during the gestational process, the ideal...
-
Fanconi anemia (FA) patients show an increased predisposition to squamous cell carcinomas (SCC). Tumors, being complex cellular ecosystems, are composed of a myriad of different cell types including malignant cells, infiltrating immune cells, fibroblasts, and endothelial cells. Interactions among these cell types can determine the...
-
Fanconi anemia (FA) is a rare inherited bone marrow failure syndrome characterized by chromosomal abnormalities and increased susceptibility to cancer. Allogeneic bone marrow transplantation is currently the only treatment for bone marrow failure, but its use is limited by the need for a suitable donor...
-
Correcting FA mutations in all cells of the body may prevent issues such as bone marrow failure and cancer in people with FA. Since mutations in FA genes start during the gestational process, the ideal time to correct genes may be in utero. The goal...
-
Studying a rare disease such as Fanconi anemia is challenging: data must be captured from as many treatment locations as possible. No single institution can have a breakthrough; it requires sharing as much data as possible from as many individuals as possible. Since 2015, Data...
-
Individuals with FA have a higher risk of developing head and neck squamous cell carcinoma (HSNCC) at young ages. Long-term survival rates remain low because often these patients cannot tolerate conventional chemotherapy and radiation treatments due to issues related to toxicity. This study is the...
-
The FA population carries a high risk for squamous cell carcinoma (SCC) of the oropharyngeal and anogenital regions connected with high morbidity and mortality. In addition to intrinsic genetic instability, hematopoietic stem cell transplantation (HSCT) and a number of other factors contribute to the pathogenesis...
The Latest
News & Events
Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.
April 15, 1983 – December 27, 2017By Daisy & Marzban Ardeshir The story below was shared by Imroze’s parents, Daisy and Marzban Ardeshir, in remembrance of their daughter’s strength, grace, and enduring spirit. Our second child, Imroze, was diagnosed with...
We’re thrilled to share that Rena and Paul Rice, parents of two children with Fanconi anemia—Sydney (19) and Blake (25)—have made an extraordinary commitment to the FA community: a gift of $100,000 per year for the next three years to...